Report topline data for the HOPE-3 clinical trial
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 29 Sep 2023
- Due
- 31 Dec 2024
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Topline data for HOPE-3 is expected in the fourth quarter of 2024.”
What we found
Evidence strength A What the grades mean
The company did not report topline data for the HOPE-3 trial by the end of 2024, with later filings indicating the data was expected in the fourth quarter of 2025.
-
A Capricor Therapeutics, Inc. 10-Q filed 2025-11-10
“Topline HOPE-3 data are expected in the coming weeks (fourth quarter of 2025)” ✓ confirmed on the page
-
A Capricor Therapeutics, Inc. 10-Q filed 2025-08-11
“HOPE-3 data (expected to be available in the fourth quarter of 2025)” ✓ confirmed on the page
Market reaction: the shares moved -9.7% against the S&P 500 over the three sessions around the disclosure (8 Aug 2025 to 13 Aug 2025). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +273 days
- 2 versions
-
Version 1 · original · stated 29 Sep 2023
Deadline 31 Dec 2024 (“in the fourth quarter of 2024”) · wording aspirational
-
Version 2 · stated 11 Jul 2025
Deadline 30 Sep 2025 (“in the third quarter of 2025”) · wording aspirational
“The HOPE-3 trial is a randomized, double-blind, placebo-controlled clinical trial of 104 patients, with topline results expected in the third quarter of 2025.”
-
Version 3 · stated 11 Aug 2025
Deadline 31 Dec 2025 (“in the fourth quarter of 2025”) · wording expected
“topline results are expected to be available in the fourth quarter of 2025.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- HOPE-3 topline data
- Language
- Aspirational (“aims”, “intends”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Capricor Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-CAPR-002533 · Corrections policy